![Ross Breckenridge](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ross Breckenridge
Chief Executive Officer at Arjuna Therapeutics
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Charlie Sheppard | M | - |
Arjuna Therapeutics
![]() Arjuna Therapeutics Medical/Nursing ServicesHealth Services Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge. | - |
Graeme Martin | M | - |
Arjuna Therapeutics
![]() Arjuna Therapeutics Medical/Nursing ServicesHealth Services Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge. | - |
Tamara Elias | M | 53 | 4 years | |
Tatiana López del Río | F | - |
Arjuna Therapeutics
![]() Arjuna Therapeutics Medical/Nursing ServicesHealth Services Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge. | - |
Darren Bianchi | M | - |
Arjuna Therapeutics
![]() Arjuna Therapeutics Medical/Nursing ServicesHealth Services Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge. | - |
Robert Barnes | M | - |
Arjuna Therapeutics
![]() Arjuna Therapeutics Medical/Nursing ServicesHealth Services Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Leigh F. Elkolli | F | - | - | |
Katrina L. Thompson | F | 65 | 14 years | |
Stephen Oesterle | M | 73 | 1 years | |
Brandi Roberts | F | 50 | 2 years | |
Anne Jillian Keating | F | 70 | 7 years | |
Gordon E. Nye | M | 69 | 18 years | |
C. Larkin | M | 75 | 2 years | |
Robert K. Schultz | M | 68 | 14 years | |
R. Huennekens | M | 59 | 3 years | |
Regina Groves | F | 66 | 4 years | |
Richard Kimes | M | 62 | 2 years | |
Donald K. Brandom | M | 64 | 13 years | |
David Eisler | M | 45 | 1 years | |
Joann Lofgren Yao | F | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
Australia | 15 | 75.00% |
Spain | 5 | 25.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ross Breckenridge
- Personal Network